Hagiwara Hiroki

ハギワラヒロキ | Hagiwara Hiroki

Affiliation and department：
Homepage URL (1)： http://kaken.nii.ac.jp/d/r/80276732.ja.html

Research field (3)： Rehabilitation science , Neuroscience - general , Neurology

Research keywords (40)： taurine , stretching , skeletal muscle stem cells , sirtuin 1 , sarcopenia , resveratrol , regenerative medicine , peripheral nerves , oxidative stress , osteopontin , neuroscience , neurorehabilitation , neuromuscular junction , myostatin , myokine , myogenic regulatory factor , muscular dystrophy , muscle atrophy , molecular cell biology , mitochondrial disease , mdx mouse , matrix metalloproteinase , LARGE , laminin , histone deacetylase inhibitor , glycan , fibrosis , extracellular matrix , exercise therapy , dystroglycan , dy mouse , disuse muscle atrophy , cytokine , congenital muscular dystrophy , caveolin-3 , bone marrow transplantation , biglycan , antioxidant potential , animal model , agrin

Research theme for competitive and other funds (20)：

2022 - 2025 サルコペニア肥満の進行と運動介入におけるマイオカインとしてのBDNFの基礎的検討
2019 - 2022 先進的ゲノム編集技術を用いた難治性神経筋疾患に対する治療戦略
2019 - 2022 Effects of inactivity and exercise intervention on brain-derived neurotrophic factor BDNF
2016 - 2019 Evaluation of combined effect of stretching and resveratrol oral administration by using new muscle atrophy induction method
2016 - 2019 Significance of dystroglycan processing and its participation in the pathogenesis of neuromuscular disorders

2015 - 2018 Elucidation of the relationship between microscopic damage to the muscle and oxidative stress during muscle atrophy and reloading.

2015 - 2018 Therapeutic strategy for muscular dystrophy via regulation of STIM1 mediated Ca2+ homeostasis

2014 - 2017 Development of glycosyltransferase replacement therapy for muscular dystrophy caused by alpha-dystroglycanopathy

2014 - 2017 Molecular mechanism of stem cell-inducing reprogramming by epithelial mesenchymal transition

2013 - 2016 Characterization of the function of dystroglycan N-terminal domain and its related disorders in nervous system

2013 - 2015 Long-term therapeutic potential of resveratrol on the progression of muscle atrophy in a mouse model of congenital muscular dystrophy

2011 - 2013 characterization of the laminin-dystroglycan interaction in neuropathy and its therapeutic application

2009 - 2011 Occupational therapy program for the patient with severest neuromuscular disease of the YES/NO judgment device adaptation level

2009 - 2011 Therapeutic strategy for muscular dystrophy by restoring the function of dystroglycan

2008 - 2010 Evaluation of matrix metalloproteinase inhibitors for the therapy for muscular dystrophy

2006 - 2007 Basic study for regenerative medicine in muscular dystrophy by myogenic stem cells

2004 - 2005 Basic study for regenerative medicine in muscular dystrophy by bone marrow transplantation

2002 - 2004 Basic research developing a therapy for muscular dystrophy by modulating intracellular signal transduction

1996 - 1998 CHARACTERIZATION OF DYSTROGLYCAN-LAMININ INTERACTION IN PERIPHERAL MYELINOGENESIS AND ITS DISTURBANCE

1996 - 1996 Agrinによる神経筋シナプス形成とその障害

Show all

Papers (27)：

Yutaka Ohsawa, Hideaki Ohtsubo, Yoshihiko Saito, Shinichiro Nishimatsu, Hiroki Hagiwara, Tatsufumi Murakami, Ichizo Nishino, Yoshihide Sunada. Caveolin 3 suppresses phosphorylation-dependent activation of sarcolemmal nNOS. Biochemical and Biophysical Research Communications. 2022
Miki Ikeda, Mariko Taniguchi-Ikeda, Takema Kato, Yasuko Shinkai, Sonoko Tanaka, Hiroki Hagiwara, Naomichi Sasaki, Toshihiro Masaki, Kiichiro Matsumura, Masahiro Sonoo, et al. Unexpected Mutations by CRISPR-Cas9 CTG Repeat Excision in Myotonic Dystrophy and Use of CRISPR Interference as an Alternative Approach. Molecular therapy. Methods & clinical development. 2020. 18. 131-144
相原正博, 斉藤史明, 丸山仁司, 萩原宏毅. 廃用性筋萎縮の病態と再荷重の過程における骨格筋と筋内血管の応答. 国際エクササイズサイエンス学会誌. 2019. 2. 1. 16-16
Yutaka Ohsawa, Hiroki Hagiwara, Shin-Ichiro Nishimatsu, Akihiro Hirakawa, Naomi Kamimura, Hideaki Ohtsubo, Yuta Fukai, Tatsufumi Murakami, Yasutoshi Koga, Yu-Ichi Goto, et al. Taurine supplementation for prevention of stroke-like episodes in MELAS: A multicentre, open-label, 52-week phase III trial. Journal of Neurology, Neurosurgery and Psychiatry. 2018
Wakana Katsuta, Masahiro Aihara, Noboru Hirose, Fumiaki Saito, Hiroki Hagiwara. Changes in oxidative stress severity and antioxidant potential during muscle atrophy and reloading in mice. Journal of Physical Therapy Science. 2018. 30. 1. 42-46

ｍore...

MISC (165)：

三樹あずさ, 河口日香瑠, 相原正博, 萩原宏毅. サルコペニア肥満モデルマウスにおけるマイオカインBDNFの解析. 日本サルコペニア・フレイル学会雑誌. 2023. 7. Suppl. 234-234
三樹あずさ, 河口日香瑠, 相原正博, 萩原宏毅. サルコペニア,サルコペニア肥満,運動習慣がマイオカインBDNFに与える影響. 日本筋学会学術集会・筋ジストロフィー医療研究会合同学術集会プログラム・抄録集. 2023. 9回・10回. 152-152
相原正博, 三樹あずさ, 萩原宏毅. 廃用性筋萎縮の病態および運動介入時における筋衛星細胞の活性化に関与するLIFとHGFの変動. 基礎理学療法学. 2023. 25. Suppl.1. 71-71
三樹あずさ, 相原正博, 萩原宏毅. 不活動およびそれに対する運動介入が各組織のBDNFに及ぼす影響の基礎的検討血中、骨格筋、脳における動態の比較. 理学療法科学. 2022. 37. 特別号6. 6-6
相原正博, 三樹あずさ, 萩原宏毅. 廃用性筋萎縮に対する運動介入が骨格筋中のLeukemia inhibitory factorに与える影響の検討. 日本筋学会学術集会プログラム・抄録集. 2021. 7回. 130-130

ｍore...

Work history (1)：

2007 - Teikyo University of Science & Technology

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page